Stephen Wesley Mitchell

6509458, Jan 21, 2003

Sep 30, 1999

09/410132

Daniel E. Afar - Pacific Palisades CA
Rene S. Hubert - Los Angeles CA
Stephen Chappell Mitchell - Santa Monica CA

Agensys, Inc. - Santa Monica CA

C07H 2104

536 235, 536 231, 4353201, 435325, 435 691

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

6652859, Nov 25, 2003

Sep 30, 1999

09/409938

Daniel E. Afar - Pacific Palisades CA
Rene S. Hubert - Los Angeles CA
Arthur B. Raitano - Los Angeles CA
Stephen Chappell Mitchell - Santa Monica CA

Agensys, Inc. - Santa Monica CA

A61K 3900

4241851, 530326, 530350, 4242771

Novel testis-specific genes and encoded proteins (PTANs) are described. PTANs are over-expressed in prostate cancer. The nucleotide and amino acid sequences of three distinct PTAN isoforms, designated PTAN-1, PTAN-2 and PTAN-3 are provided. The PTANs show no homology to any known gene. The testis-specific expression profile of PTAN in normal adult tissues, combined with the over-expression observed in prostate tumor xenografts, suggests that PTAN may be aberrancy over-expressed in at least some prostate cancers, and thus may be a useful diagnostic and/or therapeutic target for prostate cancers.

6833438, Dec 21, 2004

Dec 6, 1999

09/455486

Daniel E. Afar - Pacific Palisades CA
Rene S. Hubert - Los Angeles CA
Arthur B. Raitano - Los Angeles CA
Douglas C. Saffran - Los Angeles CA
Stephen Chappell Mitchell - Santa Monica CA

Agensys, Inc. - Santa Monica CA

C07K 1100

530350, 514 2, 514 21, 435975

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed âSTEAPâ ( ix ransmembrane pithelial ntigen of the rostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a âserpentineâ manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer.

6887975, May 3, 2005

Dec 6, 2001

10/010667

Daniel E. Afar - Pacific Palisades CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas C. Saffran - Los Angeles CA, US
Stephen Chappell Mitchell - Santa Monica CA, US

Agensys, Inc. - Santa Monica CA

A61K038/00
A61K039/00
A61K039/395
G01N033/48

530300, 4241841, 4241301, 435 723

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-is highly over-expressed in certain other human cancers.

7037667, May 2, 2006

Jul 12, 2000

09/615285

Daniel E. H. Afar - Pacific Palisades CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas Saffran - Los Angeles CA, US
Stephen C. Mitchell - Santa Monica CA, US
Aya Jakobovits - Beverly Hills CA, US
Mary Faris - Los Angeles CA, US
Igor Vivanco - Los Angeles CA, US

Agensys, Inc. - San Diego CA

G01N 33/574
G01N 33/48
C12Q 1/68

435 723, 435 6, 436 64

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. ). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.

7053186, May 30, 2006

Dec 6, 2001

10/011095

Daniel E. Afar - Pacific Palisades CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas C. Saffran - Los Angeles CA, US
Stephen Chappell Mitchell - Santa Monica CA, US

Agensys, Inc. - Santa Monica CA

C07K 16/00
C12P 21/08

5303877, 5303871, 53038815

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STREPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STREP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

7432346, Oct 7, 2008

Dec 30, 2002

10/334561

Daniel E. Afar - Pacific Palisades CA, US
Rene S. Hubert - Los Angeles CA, US
Stephen Chappell Mitchell - Santa Monica CA, US

Agensys, Inc. - Santa Monica CA

C07K 14/00
C07K 1/00
C07K 16/00

530350, 53038821

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

7485299, Feb 3, 2009

Oct 10, 2006

11/546008

Daniel E. Afar - Pacific Palisades CA, US
Rene S. Hubert - Los Angeles CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas C. Saffran - Los Angeles CA, US
Stephen Chappell Mitchell - Santa Monica CA, US

Agensys, Inc. - Santa Monica CA

A61K 39/395

4241301, 424 91

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer.